Edmund K. Waller, MD, PhD, FACP, completed his undergraduate degree at Harvard University in 1978, his MD-PhD degree at Cornell-Rockefeller in 1985, and his clinical training in Oncology at Stanford University in 1991. As a post-doctoral Fellow at Stanford from 1991 – 1993, he studied the fate of human immune cells in immune-deficient mice with Dr. Irving Weissman. Dr. Waller was recruited to Emory University in 1994 and promoted to a tenured Professor of Hematology and Medical Oncology, Medicine, and Pathology at Emory University in 2005. He has served as the Director of the Bone Marrow and Stem Cell transplant Program since 1998. Under his leadership, the annual number of stem cell transplants performed at Emory has risen from 93 in 2000 to 450 in 2018. Dr. Waller’s research is funded by the National Cancer Institute, National Heart Lung and Blood Institute as well as the National Marrow Donor Program and the American Society of Hematology. His research focuses on optimizing antitumor immunity in cancer patients. He has developed novel strategies of regulating immune responses by studying the interaction between T cells and dendritic cells in murine models and using clinical samples from patients. Dr. Waller is the author of over 280 peer-reviewed articles with an h-index of 45. He has trained 30 post-doctoral fellows and directly supervised 8 graduate students. Projects in his laboratory include graft engineering to select donor dendritic cell subsets that enhance graft versus leukemia activities and post-transplant immune reconstitution, novel drugs that target coinhibitory immune pathways and regulate graft-versus-host disease, and development of more effective ways to generate and expand cancer-specific T cells for adoptive therapy. The clinical translational focus of his research is in immunotherapy to treat patients with hematological and solid tumor malignancies, including patients undergoing autologous and allogeneic stem cell transplantation.